Literature DB >> 21497380

Treatment of vesicoureteral reflux in adults by endoscopic injection.

Katherine Moore1, Stéphane Bolduc.   

Abstract

OBJECTIVES: To prospectively evaluate the efficacy of endoscopic injection in the adult population with vesicoureteral reflux (VUR). The search for VUR is a part of the standard workup of children with febrile urinary tract infections. However, VUR can present later in life and should be investigated in the case of recurrent pyelonephritis.
METHODS: From 2005 to 2009, 27 postpubertal patients (3 males and 24 females) were treated endoscopically with injection of polydimethylsiloxane (Macroplastique) in 13 or dextranomer/hyaluronic acid copolymer (Deflux) in 14 patients; 41 renal units were injected. The median age was 23 years (range 12-65). The VUR was evaluated as grade I in 5 ureters, grade II in 28, grade III in 7, and grade IV in 1. The indications for surgery were recurrent pyelonephritis in all patients, except for 1. Of the 27 patients, 5 (12%) had undergone previous ureteral surgery. The patients were followed up with renal ultrasonography and voiding cystourethrography.
RESULTS: VUR was corrected in 38 (93%) of 41 ureteral units. Of the 3 failures, 1 patient had a large Hutch diverticulum and another had previously undergone ureterocele incision. All the patients with treatment failure had been injected with dextranomer/hyaluronic acid copolymer. Thus, the success rate was 100% with polydimethylsiloxane and 87% with dextranomer/hyaluronic acid copolymer. De novo hydronephrosis appeared in 1 renal unit. The obstruction was confirmed by a mercaptoacetyltriglycine-Lasix technetium-99m scan and treated with temporary diversion using a double-J stent.
CONCLUSIONS: Endoscopic injection is an effective treatment of VUR after puberty. In cases of recurrent pyelonephritis, imaging should be mandatory to detect scars and VUR because the endoscopic treatment is simple and noninvasive and has a good success rate, comparable to that reported for children. Crown
Copyright © 2011. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21497380     DOI: 10.1016/j.urology.2010.12.080

Source DB:  PubMed          Journal:  Urology        ISSN: 0090-4295            Impact factor:   2.649


  5 in total

Review 1.  Vesicoureteral reflux: From prophylaxis to surgery.

Authors:  Anne-Sophie Blais; Stéphane Bolduc; Katherine Moore
Journal:  Can Urol Assoc J       Date:  2017 Jan-Feb       Impact factor: 1.862

2.  Management of Vesicoureteral Reflux by Endoscopic Injection of Dextranomer/Hyaluronic Acid in Adults.

Authors:  Timothy W Stark; John M Lacy; David M Preston
Journal:  Rev Urol       Date:  2016

3.  Late presentation of vesicoureteral reflux: An unusual cause of pyelonephritis in adults.

Authors:  Bernardo Pereira; Catarina Macedo; Sara Anacleto; Marina Gonçalves; Estêvão Lima; Emanuel Carvalho-Dias
Journal:  Int J Surg Case Rep       Date:  2018-10-29

Review 4.  Management of Vesicoureteral Reflux: What Have We Learned Over the Last 20 Years?

Authors:  Göran Läckgren; Christopher S Cooper; Tryggve Neveus; Andrew J Kirsch
Journal:  Front Pediatr       Date:  2021-03-31       Impact factor: 3.418

5.  Injection Pharyngoplasty With a Hyaluronic Acid and Dextranomer Copolymer to Treat Velopharyngeal Insufficiency in Adults.

Authors:  Brandon W Peck; Becky S Baas; Shelagh A Cofer
Journal:  Mayo Clin Proc Innov Qual Outcomes       Date:  2017-08-02
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.